Amgen Inc.

Vigil Neuroscience, Inc.

Maxence Bos

Jonathan B Houze

Ryan D White

Gwenaella Rescourio

Haoxuan Wang

Vincent Santora

Yongwei Wu

Alice R Wong

Timothy Hopper

Lara C Czabaniuk

Jane Panteleev

John Mancuso

Ivan Franzoni

The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2”). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ('TREM2').  This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Growing community of inventors

Saint-Laurent, Canada

Maxence Bos